Insider Watch: 5 Stocks Scott D. Sandell Likes

Scott Sandell, a large shareholder and director with over 30 affiliations is the insider to watch for retail investors. He is the general partner of New Enterprise Associates. We have picked his five largest stakes in terms of value.

Groupon Inc (NASDAQ:GRPN)

Sandell, has the largest position in Groupon Inc (NASDAQ:GRPN). He holds 54.24 million class A shares, with a value of around $588 million. In August 2013 he sold 35,287 shares. His sentiment, though has remained bullish, unlike the high prices associated with most acquisitions. New Enterprise Associates is the company that backed Groupon prior to its IPO and held 43.73 million class A shares received in the IPO.

A couple of days back, Groupon, acquired Ideeli, a leading online flash fashion retailer, to further extend its presence in fashion and apparel. The deal was closed for $43 million in cash. Ideeli, a short-lifecycle, flash-sale online company is very small sized in comparison to Groupon’s global leadership, and has left most investors unimpressed.

Aside from Sandell, Theodore Leonsis, director at Groupon now holds 793,546 shares, sold 19,750 shares a week ago. P Eric Lefkofsky, chief executive officer also sold 454,166 shares recently.

Another company that has held Scott Sandell’s interest is TESARO Inc. (NASDAQ:TSRO).Sandell holds 9.85 million shares valued at $323 million. TESARO Inc. (NASDAQ:TSRO) is an oncology-focused biopharmaceutical company dedicated to improving the lives of cancer patients by acquiring, developing and commercializing safer and more effective therapeutics. Rolopitant is a product the company has developed to prevent nausea and vomiting due to chemotherapy.

The company has recently reported successful results of the primary endpoint for Rolapitant and seeks US Food and Drug Administration approval, which is a good sign for its investors, including Mr. Sandell.

Joseph Edelman‘s Perceptive Advisors, has 4.75% of its 13F portfolio invested in Tesaro Inc, and holds 1.51 million shares. Columbus Circle Investors increased its holdings in the company by a sixfold in the third quarter of last year and now holds 671,500 shares.

In the meanwhile SEC filings for Epizyme, Inc. (NASDAQ:EPZM) states that Scott Sandell holds a position on 6.44 million shares valued at $242 million. In November 2013 he purchased 406,500 shares.

Epizyme is a clinical stage biopharmaceutical company creating personalized therapeutics for patients with genetically defined cancers. Epizyme has built a proprietary product for histone methyltransferases, or HMTsm known as epigenetics, that control gene expression. Genetic alterations or mutations may result in oncogenisis. By focusing on the genetic drivers of cancers, Epizyme’s targeted science seeks to match the right medicines with the right patients for a personalized approach to cancer treatment.

A Robert Copeland, executive vice-president at Epizyme, trimmed his holdings by 15,006 shares on January 13, and now holds 25,931 shares. J Robert Gould, president and CEO, also sold 30,000 shares in the first week of January.

A couple of days ago, Mr. Sandell has decreased his stake in Cvent Inc (NYSE:CVT) significantly. The investor disposed over 1.13 million shares that have been sold at $35.5 apiece. Even following the sale, Sandell holds a large position in the company, 6.16 million shares worth $225.5 million.

Cvent Inc (NYSE:CVT) operates a cloud-based enterprise event management platform. It went public last August and since then its stock gained around 10%. However, many investors expressed their interest in the newly public company, and in the previous round of 13F filings, 15 funds out of those we track reported adding Cvent Inc (NYSE:CVT) to their equity portfolio. Drew Cupps’ Cupps Capital Management owns the largest stake, which contains around 221,300 shares.

Scott Sandell continues to remain an important investor in Clovis Oncology Inc (NASDAQ:CLVS) as he holds 2.28 million shares valued at $166.42 million. Clovis Oncology, Inc. is a bio-pharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents. Clovis Oncology targets development programs at specific subsets of cancer populations, and simultaneously develops diagnostic tools that direct a compound in development to the population that is most likely to benefit from its use. In its press release, it announced FY14 and likely development milestones that are to be achieved. Initial stage studies would commence for its cell lung cancer before June 2014. It’s ovarian cancer drug –rucaparib- will see patient recruitment to begin.

Partner Fund Management, led by Christopher Medlock James holds 2.03 million shares of Clovis Oncology, worth $123.24 million. Steven Cohen‘s SAC Capital Advisors, also has 1.09 million shares in its equity portfolio.

blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

10 Cities with High Demand for Nurses

6 of the Worst Greeting Card Messages Ever Crafted

6 Ways to Make Money in ArcheAge and Build Your Empire

10 Foods To Eat To Lower Cholesterol Levels

The 10 Most Hated Television Characters of All Time

The 30 Worst Halloween Costume Ideas Ever Brought to Horrible Life

10 Vocational Skills in Demand Today with Jobs Waiting to be Filled

10 Best Places to Visit in Central and South America

The 10 Greatest Empires in History Which Nearly Conquered the World

The 6 Cheapest Boarding Schools In America 2015

5 Clear Reasons LoL is Better than DotA, Continues to Rule MOBAs

The Only 9 Teams with a Chance to Win the Super Bowl

The 15 Most Common Phobias in America that Induce Fits of Panic

Top 6 Least Expensive Tourist Destinations in 2014

Jim Goetz, Peter Fenton, Jim Breyer: Top 6 Venture Investors for 2014

Top 15 Billionaires in 2014

5 Pitfalls To Avoid When Buying a Franchise

Top 20 Medical Schools in the US – 2014 Rankings

4 Business Strategies that Turned Jamie Oliver into the World’s Richest Chef

6 Qualities That Make You A Good Team Player

10 High Paying Seasonal Jobs in America this Holiday Season

The 10 Busiest Shipping Lanes in the World

5 Most Valuable Brands in China

The 10 States with Highest Substance Abuse Rates Crippling Their Populace

The Top 10 Things to Do Before You Die That Will Echo for Eternity

The 10 Best Selling Items on Etsy

Top 10 Things to Do in Tokyo, the Greatest City in the World

10 Mistakes on Social Media that Can Harm You and Will Probably Get You Canned

The 10 Best Cities to Find Jobs in 2014

The 10 Most Controversial Songs Of All Time to Hit (and get Banned from) the Airwaves

The 20 Biggest IPOs in US History

The 10 Best Places to Visit in Mexico that Are Beautiful and Safe

7 Bad Habits that Age You Beyond Your Years

The 40 Best Fortune Cookie Sayings That Will Leave You Bemused, Befuddled, or Beguiled

10 Foods to Eat Before a Workout to Make Every Drop of Sweat Count

The 5 Best Documentaries On Netflix You Must See

The Most Heartwarming and Inspirational Story Of This Halloween Season, It Will Make You Cry and Jump For Joy

10 Best Party Songs of All Time to Bring the House Down With

5 New World Order Conspiracy Theories that Will Strangle the World

The 10 Highest Rated Movies of 2014

The 10 Largest Container Shipping Companies in the World

The 10 Largest Armies in the World: Who Should We Be Afraid Of?

Best Warren Buffett Quotes on Money You Need to Hear

The 10 Highest Suicide Rates by Profession

The 20 Most Underrated Movies of All Time

The 10 Fastest Growing Companies in America

The 10 Biggest Outlet Malls in USA

The 5 Most Popular Rap Songs of All Time

The 10 Countries that Eat the Most Meat

The10 Most Expensive Countries to Fly To

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!